Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CFO Blaine Davis Sells 4,028 Shares

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) CFO Blaine Davis sold 4,028 shares of the business’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $16.83, for a total transaction of $67,791.24. Following the completion of the transaction, the chief financial officer now owns 94,811 shares of the company’s stock, valued at $1,595,669.13. This trade represents a 4.08 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Blaine Davis also recently made the following trade(s):

• On Friday, January 3rd, Blaine Davis sold 3,961 shares of Cartesian Therapeutics stock. The shares were sold at an average price of $16.72, for a total value of $66,227.92.

Cartesian Therapeutics Stock Performance

NASDAQ RNAC opened at $16.92 on Friday. The stock has a market capitalization of $430.02 million, a price-to-earnings ratio of -0.32 and a beta of 0.56. Cartesian Therapeutics, Inc. has a 52 week low of $11.66 and a 52 week high of $41.87. The stock’s 50 day moving average price is $19.08 and its two-hundred day moving average price is $18.13.

Institutional Trading of Cartesian Therapeutics

A number of institutional investors have recently made changes to their positions in the business. BNP Paribas Financial Markets grew its position in Cartesian Therapeutics by 122.5% in the third quarter. BNP Paribas Financial Markets now owns 1,651 shares of the company’s stock valued at $27,000 after purchasing an additional 909 shares in the last quarter. Point72 DIFC Ltd acquired a new position in shares of Cartesian Therapeutics during the 2nd quarter worth about $47,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Cartesian Therapeutics in the 2nd quarter valued at about $49,000. JPMorgan Chase & Co. increased its position in shares of Cartesian Therapeutics by 0.9% in the third quarter. JPMorgan Chase & Co. now owns 309,018 shares of the company’s stock valued at $4,981,000 after acquiring an additional 2,688 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Cartesian Therapeutics by 2.1% during the third quarter. Geode Capital Management LLC now owns 135,700 shares of the company’s stock worth $2,188,000 after acquiring an additional 2,737 shares in the last quarter. Institutional investors own 86.95% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on RNAC shares. Cantor Fitzgerald raised Cartesian Therapeutics to a “hold” rating in a research note on Monday, December 2nd. HC Wainwright reissued a “buy” rating and set a $45.00 price target (up from $41.00) on shares of Cartesian Therapeutics in a research note on Wednesday, December 4th. BTIG Research began coverage on Cartesian Therapeutics in a research report on Thursday, December 19th. They issued a “buy” rating and a $42.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $41.00 target price on shares of Cartesian Therapeutics in a report on Tuesday, December 3rd. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $42.86.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.